BACKGROUND: Current cell-free DNA assessment of fetal chromosomes does not analyze and report on all chromosomes. Hence, a significant proportion of fetal chromosomal abnormalities are not detectable by current noninvasive methods. Here we report the clinical validation of a novel noninvasive prenatal test (NIPT) designed to detect genomewide gains and losses of chromosomal material 7 Mb and losses associated with specific deletions <7 Mb. OBJECTIVE: The objective of this study is to provide a clinical validation of the sensitivity and specificity of a novel NIPT for detection of genomewide abnormalities. STUDY DESIGN: This retrospective, blinded study included maternal plasma collected from 1222 study subjects with pregnancies at increased risk for fetal chromosomal abnormalities that were assessed for trisomy 21 (T21), trisomy 18 (T18), trisomy 13 (T13), sex chromosome aneuploidies (SCAs), fetal sex, genomewide copy number variants (CNVs) 7 Mb, and select deletions <7 Mb. Performance was assessed by comparing test results with findings from G-band karyotyping, microarray data, or high coverage sequencing.
Introduction
Since its introduction in 2011, noninvasive prenatal tests (NIPT) have had a significant impact on prenatal care. In only 4 years, NIPT has evolved into a standard option for high-risk pregnancies. 1 Content has also evolved from exclusive trisomy 21 (T21) testing to include trisomy 18 (T18), trisomy 13 (T13), sex chromosome aneuploidies (SCAs), and select microdeletions. This standard content can be expected to detect 80-83% of chromosomal abnormalities detected by karyotyping in a general screening population, [2] [3] [4] however this leaves a gap of approximately 17-20% of alternative chromosomal/subchromosomal abnormalities not detected. Consequently, obtaining comprehensive information about the genetic makeup of the fetus requires an invasive procedure. To overcome these limitations, NIPT could be extended to cover the entire genome. However, it is challenging to maintain a very high specificity and positive predictive value (PPV) when interrogating all accessible regions in the genome. 5 In previous reports, we have overcome these technical hurdles. 6 Furthermore, a recent study by Yin et al 7 demonstrated feasibility for noninvasive genomewide detection of subchromosomal abnormalities. In this report, we have improved the assay and statistical methods to enable comprehensive genomewide detection of copy number variants (CNVs) 7 Mb. We present results of a large blinded clinical study of >1200 samples including >100 samples with common aneuploidies detectable by traditional NIPT and >30 samples affected by subchromosomal CNVs.
Materials and Methods Study design
This blinded, retrospective clinical study included samples from women considered at increased risk for fetal aneuploidy based on advanced maternal age 35 years, a positive serum screen, an abnormal ultrasound finding, and/or a history of aneuploidy. Archived samples were selected for inclusion in the study by an unblinded internal third party according to the requirements documented in the study plan. Samples were then blind-coded to all operators and the analysts who processed the samples. After sequencing, an automated bioinformatics analysis was performed to detect whole chromosome aneuploidies and subchromosomal CNVs. Results were compiled electronically and were reviewed by a subject matter expert who assigned the final classification. This manual review mimics the process in the clinical laboratory, where cases are reviewed by a laboratory director before a result is signed out. Completed classification results were provided to the internal third party for determination of concordance. Analyzed samples had confirmation of positive or negative events by either G-band karyotype or microarray findings from samples collected through either chorionic villus sampling (CVS) or amniocentesis. Circulating cell-free "fetal" DNA is believed to originate largely from placental trophoblasts. Genetic differences between the fetus and the placenta can occur (eg, confined placental mosaicism), leading to discordance between NIPT results and cytogenetic studies on amniocytes or postnatally obtained samples. 8 Results from CVS by chromosomal microarray were thus considered the most accurate ground truth. Therefore, discordant results originating from amniocytes (karyotype or microarray) were resolved by sequencing at high coverage (an average of 226 million reads per sample). Sequencing depth has been shown as the limiting factor in NIPT methods, with increased depth allowing improved detection of events in samples with lower fetal fractions or improved detection of smaller events. 9 High coverage sequencing has been used in multiple studies to unambiguously identify subchromosomal events 6,10-12 and was used here as a reference for performance evaluation in discrepant amniocentesis samples.
Details of the sample demographics are described in Table 1 ½T1 . Indications for invasive testing are described in Table 2 ½T2 .
Sample collection
In total, 1222 maternal plasma samples were previously collected using 4 investigational review board (IRB)-approved protocols with a small subset (9 samples) comprising remnant plasma samples collected from previously consented patients in accordance with the Food and Drug Administration guidance Q2 on informed consent for in vitro diagnostic devices using leftover human specimens that are not individually identifiable (April 25, 2006) . Samples from 2 of the protocols (Compass IRB no. 00508 and WIRB Q3 no. 20120148) were collected from high-risk pregnant subjects prior to undergoing a confirmatory invasive procedure (1189 samples). Samples from the other 2 protocols (Compass IRB no. 00351 and Columbia University IRB no. AAAN9002) came from subjects who were enrolled in the studies after receiving the fetal karyotype and/or microarray results of a confirmatory invasive procedure (24 samples). All subjects provided written informed consent prior to undergoing any studyrelated procedures. A total of 5321 high-risk subjects were recruited into the 4 clinical studies indicated above at the time of sample selection. To be eligible for inclusion into this study, subjects had to have met all protocol inclusion and no exclusion criteria, have fetal outcome determined by karyotype and/or microarray, and have at least 1 plasma aliquot of 3.5 mL obtained from whole blood collected in a BCT tube (Streck, Omaha, NE). There Q4 was no sample selection preference based on high-risk indication. All subjects meeting these selection criteria with an abnormal fetal outcome as needed for the study were identified and pulled from inventory. These were then supplemented with randomly selected subjects with samples meeting the same selection criteria but with a normal karyotype to reach the total of 1222 samples for testing.
Library preparation, sequencing, and analytical methods
Libraries were prepared and quantified as described by Tynan et al. 13 To reduce noise and increase signal, sequencing depth for this analysis was increased to target 32 million reads Q5 per sample. Sequencing reads were aligned to hg19 using Bowtie 2. 14 The genome was then partitioned into 50-kbp nonoverlapping segments and the total number of reads per segment was determined, by counting the number of reads with 5' ends overlapping with a segment. Segments with high read count variability or low mapability were excluded. The 50 kbp read counts were then normalized to remove coverage and GC biases and other Q6 higherorder artifacts using the methods previously described in Zhao et al. 6 The presence of fetal DNA was quantified using the regional counts of whole genome single-end sequencing data as described by Kim et al. 15 
Genomewide detection of abnormalities
Circular binary segmentation (CBS) was used to identify CNVs throughout the entire genome by segmenting each chromosome into contiguous regions of equal copy number. 16 A segmentmerging algorithm was then used to compensate for oversegmentation by CBS when the signal-to-noise ratio was low. 17 Z-scores were calculated for both CBS-identified CNVs and whole chromosome variants by comparing the signal amplitude with a reference set of samples in the same region. The measured Z-scores form part of an enhanced version of Chromosomal Aberration Decision Tree previously described in detail in Zhao et al. 6 To further improve specificity of CNV detection, bootstrap analysis was performed as an additional measure for the confidence of the candidate CNVs. The within sample read count variability was compared to a normal population (represented by 371 euploid samples) and quantified by bootstrap confidence level. To assess within sample variability, the bootstrap resampling described below was applied to every candidate CNV.
For each identified segment within the CNV, the median shift of segment fraction from the normal level across the chromosome was calculated. This median shift was then corrected to create a read count baseline for bootstrapping. Next, a bootstrapped segment of the same segment length as the candidate CNV was randomly sampled with replacement from the baseline read counts. The median shift was then applied to this bootstrapped fragment. The segment fraction of the bootstrapped fragment was calculated as follows:
read counts within segment P read counts across the autosome This process was repeated 1000 times to generate a bootstrap distribution of segment fractions for an affected population. A normal reference distribution was created based on the segment fraction of the same location as the candidate CNV in 371 euploid samples. A threshold was then calculated as the segment fraction that was at least 3.95 median absolute deviations away from the median segment fraction of the reference distribution. Lastly, the bootstrap confidence level was calculated as the proportion of bootstrap segments whose fractions had absolute Q7 z-statistics above the significance threshold.
A whole chromosome or subchromosomal abnormality is detected as described in Zhao et al. 6 
Results
The study comprised a total of 1222 maternal plasma samples. After unblinding, 11 samples were excluded because they had no or insufficient karyotype or microarray information ( ) and 3 samples were excluded because of confirmed mosaicism.
Of the remaining 1208 samples, 42 were flagged as nonreportable using quality criteria that had been established prior to analysis, leaving 1166 reportable samples for analyses comprising 13% (n ¼ 153) of samples with common whole chromosome 21, 18, 13, X, or Y aneuploidies and 3.6% (n ¼ 43) of samples with subchromosomal CNVs or rarer whole chromosome aneuploidies. Technical failure criteria included but were not limited to: low library concentration, low raw autosomal counts, high GC bias, poor normalization, and high bin variability ( Figure 1 ). Biological failure criteria included low fetal fraction (<4%) and large maternal CNV events. The most common reason for failure was low fetal fraction (n ¼ 11). During review of the data, 1 sample was signed out as T18 (and was included in the analyzed cohort), even though it did not meet the autosomal count minimum. This sample had sufficient counts for the determination of standard aneuploidies, but not sufficient counts for the detection of subchromosomal CNVs. The 42 nonreportable samples showed no evidence of enrichment for whole chromosome/ subchromosomal positive samples ( 223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278   279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333 T21, T18, and T13 detection   Among the 1166 reportable samples,  there were 85 T21 samples, 27 T18 samples, and 15 T13 samples ( Figure 1 ). All euploid, T21, T18, and T13 samples (determined by invasive diagnostic procedures) were classified correctly by NIPT. One sample was classified by NIPT as T21 but had a normal (46, XX) karyotype by amniocentesis (Supplemental Table 1 ). This discrepancy was adjudicated through high coverage uniplex sequencing (typically with >180 million reads) according to our study plan (Supplemental Figure 1 , D). The sample showed 16.3% fetal fraction, but the gain of genetic material from chromosome 21 was concordant with 6.5% fetal fraction. This is suggestive of confined placental mosaicism, a relatively common cause of discordant results between amniocyte results and CVS or placentally derived cell-free DNA (cfDNA) analysis. 8 Table 3 ½T3 summarizes the performance for T21, T18, and T13. For T21, the sensitivity was 100% (95% confidence interval [CI], 94.6e100%) and the specificity was 100% (95% CI, 99.6e100%). For T18, the sensitivity was 100% (95% CI, 84.4e100%) and the specificity was 100% (95% CI, 99.6e100%). For T13, the sensitivity was 100% (95% CI, 74.7e100%) and the specificity was 100% (95% CI, 99.6e100%). 335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390   391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444 445 446
SCA detection
In the 1166 samples reportable for all chromosomal abnormalities, there were 21 samples flagged as nonreportable specifically for SCA classification based on thresholds for the chromosome X zscore and chromosome Y z-score as described by Mazloom et al. 19 There was also 1 additional sample with an apparent maternal XXX that was flagged as nonreportable for SCA because the maternal event distorted the sex chromosomal representation to a degree that fetal events could not be classified. Among the remaining 1144 samples reportable for SCAs, there were 7 discordant positives that were classified as normal (46, XX) by karyotype and as XO by sequencing at 6-plex (Supplemental Table 1 ). In all discordant cases, the karyotype had been obtained from amniocyte samples. This phenomenon is well described and may be attributed to varying levels of placental or maternal mosaicism. 20 Uniplex sequencing confirmed 6 of the 7 XO samples. The seventh sample had a nonreportable result at uniplex coverage, hence the existing amniocentesis result was used as truth resulting in 1 falsepositive assignment. Overall, the sensitivity for SCA was 100% (95% CI, 84.0e100%) with a specificity of 99.9% (95% CI, 99.4e100%) ( Table 3) .
Genomewide detection of CNVs
The test was also designed to detect CNVs 7 Mb (including whole chromosome abnormalities other than T13, T18, T21, and SCAs) as well as select microdeletions <7 Mb. 5 447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502   503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558 examples of NIPT-detected CNVs confirmed by microarray or karyotype are shown in Figure 2 ½F2 . Overall, the sensitivity for detection of whole chromosome and subchromosomal abnormalities other than T13, T18, T21, and SCAs was 97.7% (95% CI, 86.2e99.9%) and the specificity was 99.9% (95% CI, 99.4e100%) ( Table 3) . One case was clearly mosaic for T22 by both standard coverage and uniplex sequencing (Supplemental Table 1 and Supplemental Figure 1 , E), but was classified as normal by microarray analysis. Because the invasive diagnosis came from microarray analysis of cells derived from CVS, our study design considered this as the gold standard, and this outcome was considered a discordant positive. Another case showed no gain or loss of genetic material with both standard and uniplex sequencing for a sample that had a 46, XX, der(12)t(12;19)(p13.1;q13.1) karyotype (Supplemental Figure 2, B) . This outcome was considered as a discordant negative given that the invasive procedure was CVS. A set of 7 samples were classified as full chromosomal trisomies, and because the karyotype or microarray results were derived from amniocytes in these cases, uniplex sequencing was performed for adjudication per the study design. The trisomy finding was confirmed in each case by uniplex sequencing, and these findings were considered as concordant positives (Supplemental Figure 1) .
In addition to the high accuracy demonstrated in the results, in some cases NIPT could also provide clarification about the origin of extra genetic material when the G-banding pattern was not sufficiently clear. In 1 case, the amniocyte karyotype finding, 46, XX, der(5)t(5;?)(p15.3;?), indicated a deletion on chromosome 5 and a duplication of unknown origin (Figure 3   ½F3 ). NIPT identified an 18.6-Mb duplication representing the entire short arm of chromosome 17, indicating this fetal tissue possessed a trisomy of chromosome 17p that was not clarified by standard karyotype. Trisomy 17p is associated with developmental delay, growth retardation, hypotonia, digital abnormalities, congenital heart defects, and distinctive facial features. 21 Additional cases are shown in Supplemental Figure 3 .
Comment
Couples and families who are seeking prenatal information about the genetic health of their baby have multiple options today, ranging from noninvasive tests that screen for select chromosomal abnormalities to invasive procedures including karyotype and microarray testing that can deliver the most comprehensive genomic assessment.
Current NIPT methods provide information about a limited set of conditions that typically include T21, T18, T13, and SCAs. In this study we expand testing to the entire genome. The results demonstrate that high sensitivity and specificity were maintained while adding genomewide clinically relevant content.
Most NIPT tests suffer from the problem of multiple hypothesis testing; when multiple regions of the genome are tested independently, false-positive rates become additive. 22 This can result in unacceptably high false-positive rates and lead to maternal anxiety and additional unnecessary clinical testing. Methods that target individual regions of the genome cannot overcome these limitations because they are part of the design of the test. 23 We have shown that these limitations can be overcome by using a genomewide approach, as described here and previously. 6 In this study we demonstrate that the test can provide excellent performance for CNVs 7 Mb and select microdeletions <7 Mb across the genome.
This study does have limitations. Although we analyze 2-to 6-fold more samples with subchromosomal CNVs than previous studies, 6, 11, 23 the total number of affected samples is still relatively small compared to studies validating Q9 performance for detection common whole chromosome web 4C=FPO
FIGURE 3
Clarification of karyotype findings by sequencing of maternal plasma Normal regions (blue). Deletions and duplications that are detected with high bootstrap confidence levels (>0.99) (red). Low bootstrap confidence events (yellow). Chromosome (Chr) 5 and 17 ideograms are shown for sample with karyotype of 46, XX, der(5)t(5;?)(p15.3;?). Unidentified duplication on karyotype is from Chr 17.
aneuploidies. 24 It remains challenging to statistically validate detection of rare individual chromosomal variations. As such we utilize samples with CNVs of varying size and location throughout the genome with varying frequency of individual occurrence. This study design with its high positivity rate allows only estimation of PPV. As sensitivity and specificity values have proven stable in previous studies when applied to the real-world samples, PPV can be considered a function of incidence rate. Incidence estimates of larger karyotype-detectable genomewide subchromosomal CNVs vary but are typically considered between 1 in 200 and 1 in 400. 25 Modeled PPVs for these incidence rates would therefore be between 68-83% (Supplemental Figure 4) . Due to the high sensitivity observed, negative predictive values are expected to be well >99.9% when incidence rates are <1 in 200. As our study utilized only 1 aliquot for analysis, our reportable rate was 96.5%, with an expected reportable rate of w99% with availability of 2 aliquots. 18 Of the 11 samples not reported due to the biological effect of low fetal fraction, all had normal karyotype result. Another challenge commonly observed in novel technologies with increased performance is the compilation of samples with appropriate ground truth. In our study we face the technical challenge of comparing sequencing vs Gband karyotype or microarray, as well as the biological aspect of cfDNA vs amniocyte or CVS. We have used a method that prioritizes CVS over amniocentesis because of the placental origin of cfDNA. 8 Factors that can lead to discordant results include confined placental mosaicism, maternal mosaicism, vanishing twins, undetected tumors, and technical errors. Consequently our method of evaluation has the potential to overestimate performance with regard to fetal outcome. However, knowledge about the genetic health of the placenta might in itself be advantageous when guiding the pregnancy, for example in the case of intrauterine growth restriction. Prospective studies using the method described here with follow-up of birth outcome will further enhance understanding of clinical effectiveness.
An interesting observation in this study was the sometimes subjective nature of karyotyping. When G-banding is used as an analytical method, the optical resolution is occasionally not sufficient to determine the origin of additional genetic material, making a clinical interpretation more difficult. These ambiguities are eliminated when using NIPT because the test requires sequencing alignment to the genome before DNA gains and losses are determined. However, G-banding will, for the foreseeable future, be the superior methodology to determine copy number neutral structural changes.
In pregnancies that can benefit from additional information, this test provides more clinically relevant results than previous NIPT options. However, its role as a follow-up test to abnormal ultrasound findings or as a general population screen will likely be debated for the foreseeable future. It has been argued that the incidence of clinically relevant subchromosomal CNVs could be as high as 1.7% in a general population, 25 and early microarray data 26 indicate that as many as 30% of subchromosomal CNVs could be >7 Mb. In consequence, the incidence for these large CNVs may be around 0.5% in the general population, substantially higher than the incidence of T21.
In summary, this clinical study provides validation for an approach that extends the clinical validity of cfDNA testing, now providing detection of T21, T18, T13, SCAs, fetal sex, and genomewide detection of subchromosomal and whole chromosomal abnormalities. Overall, subchromosomal abnormalities and aneuploidies other than T13, T18, T21, and SCAs were detected with a combined clinical sensitivity and specificity of 97.7% (95% CI, 86.2e99.9%) and 99.9% (95% CI, 99.4e100%), respectively. This enables comprehensive noninvasive chromosomal assessment that was previously available only by karyotype, and in some cases, may clarify cryptic findings otherwise identifiable only by microarray. 783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838   839  840  841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885  886  887  888  889  890  891  892  893  894 SUPPLEMENTAL 
